Article
The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment.
Journal for immunotherapy of cancer - 15 Aug 2017
Poon Edmund, Mullins Stefanie, Watkins Amanda, Williams Geoffrey S, Koopmann Jens-Oliver, Di Genova Gianfranco, Cumberbatch Marie, Veldman-Jones Margaret, Grosskurth Shaun E, Sah Vasu, Schuller Alwin, Reimer Corrine, Dovedi Simon J, Smith Paul D, Stewart Ross, Wilkinson Robert W
Abstract excerpt
BACKGROUND: T-cell checkpoint blockade and MEK inhibitor combinations are under clinical investigation. Despite progress elucidating the immuno-modulatory effects of MEK inhibitors as standalone therapies, the impact of MEK inhibition on the activity of T-cell checkpoint inhibitors remains incompletely understood. Here we sought to characterize the combined effects of MEK inhibition and anti-CTLA-4 mAb...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.